Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06076616
Other study ID # 2022-097
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2022
Est. completion date January 1, 2024

Study information

Verified date May 2024
Source Franciscus Gasthuis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prehabilitation and rehabilitation through personalized lifestyle counseling in patients with breast cancer.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 1, 2024
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion criteria 1. Woman with a confirmed breast cancer diagnosis 2. Planned surgical treatment of breast cancer 3. Age 18 years or older 4. Provision of written informed consent Exclusion criteria 1. Severe mental retardation, which limits the ability to follow instructions independently 2. Severe psychiatric problems, which limits the ability to follow instructions independently 3. Legal incapacity 4. Language barrier: If we cannot find a lifestyle coach who speaks the patient's language, unfortunately we cannot offer the lifestyle coaching in its entirety, and this option will be omitted for the patient.

Study Design


Intervention

Behavioral:
Prehabilitation and rehabilitation
A personalized lifestyle counseling programme.

Locations

Country Name City State
Netherlands Franciscus Gasthuis en Vlietland Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Franciscus Gasthuis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment/consent rate To estimate patient recruitment/consent rate to the prehabilitation/rehabilitation group Enrolment logs will be recorded for all patients who meet the eligibility criteria. Reasons for non-participation will be recorded. We define a success criterion of 40% of the total number of participants invited to be recruited to the pilot study. From baseline to 6 months postoperatively
Primary Attendance rate To estimate patient attendance, measured by the number of sessions attended out of 10. Reasons for non-attendance will be collected and withdrawals tracked. We will consider an attendance rate of 80% satisfactory From baseline to 6 months postoperatively
Primary Patient adherence To estimate patient adherence monitored with the aid of the wearables. Adherence is defined as at least 150 min of moderate intensity exercise and at least two strength training sessions per week. Exercise instructions are based on the Health Council's exercise guidelines. We will consider an adherence of 70% as satisfactory. From baseline to 6 months postoperatively
Primary Withdrawals To estimate the number of withdrawals, defined as the proportion of patients who quit the intervention before reaching the primary endpoint (HRQOL at six months after surgery). Information about the reasons for withdrawal will be collected. From baseline to 6 months postoperatively
Primary Patient satisfaction To estimate patient satisfaction with the programme assessed during three interviews: at four weeks, at three months after surgery and at the end of the study. Satisfaction is defined as: satisfaction with the lifestyle coach, satisfaction with the duration of the intervention, satisfaction with the physical training programme. Patients will be given room for their own input to improve the intervention. From baseline to 6 months postoperatively
Primary Selection bias To explore any evidence of selection bias in participants recruited into the study (assessed through participant characteristics at baseline). From baseline to 6 months postoperatively
Secondary Likely changes in Health Related Quality of Life (HRQOL) To investigate likely changes in the primary outcome measure HRQOL measured with the EORTC-QLQ-30 questionnaire at six months after surgery. Baseline, the day before surgery, 6 months postoperatively
Secondary Likely changes in BMI Body Mass Index Baseline, the day before surgery, 6 months postoperatively
Secondary Likely changes in functional capacity (physical fitness) Measured using the 6 minute walking test (6MWT) Baseline, the day before surgery, 6 months postoperatively
Secondary Likely changes in the number of postoperative complications Complications within 30 days after surgery, measured with the Comprehensive Complication Index (CCI) 30 days after surgery
Secondary Likely changes in smoking status Smoking status (yes/no) as assessed by the primary investigator Measured at baseline and 6 months postoperatively
Secondary Likely changes in postoperative functional recovery Measured the day after surgery with the MILAS and DEMMI questionnaires The day after surgery
Secondary Likely changes in mean score of the different BREAST-Q scales Measured using the BREAST-Q questionnaire The questionnaire will be administered at enrolment and at six months after surgery.
Secondary Likely changes in mean score of quality of life by means of the EORTC-BR23 questionnaire Measured using the EORTC-BR23 questionnaire The questionnaire will be administered at enrolment and at six months after surgery.
Secondary Likely changes in mean score of the different EORTC-QLQ-30 scales which will be administered at enrolment and six months after surgery. Measured using the EORTC-QLQ-30 questionnaire The questionnaire will be administered at enrolment and at six months after surgery.
Secondary Likely changes in mean score of the EQ5D-5L questionnaire Measured using the EQ-5D-5L questionnaire The questionnaire will be administered at enrolment and at six months after surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A